|
About Neelima FirthNeelima Firth is an innovative biopharmaceutical consultant with a record of turning projects into successful products based in Los Angeles.
Extensive experience in reimbursement, marketing, project management and financial analysis. Neelima has had a successful career in clinical project management, reimbursement and strategy for companies including Amgen, Bristol Myers, GSK and the Alfred Mann Foundation. She has had extensive consulting and work experience in commercialization and reimbursement including Medicare, Medicaid and Managed Care strategies, marketing, project management and financial analysis. She is the past President of the Association for Strategic Planning |
Who We Are |
A boutique consulting firm specializing in strategic planning for commercialization of life science products. Worked with small companies directly and partnered with consulting companies in the US and UK. Neelima partners with experts in strategy, scenario planning, future thinking, reimbursement and commercialization.
|
Our History |
Company was founded in 2008 and provided consulting for biotechnology and pharmaceutical companies, specifically in oncology and neurology space. Since 2010, expanded into medical devices and diagnostic devices.
Neelima has had a successful career in clinical project management, regulatory, reimbursement and strategy for companies including Amgen, BMS, GSK and the Alfred Mann Foundation. She was an early Amgen employee and established Amgen’s initial presence in the UK. At Amgen she held a variety of roles including Reimbursement, Market Access, lead on compendia and AMCP dossier creation for new products, Strategic Planning for Enbrel, managing the alliance relationship with Wyeth and the development of the Enbrel business plan. We understand what a start up and small company needs and we are not afraid to role up our sleeves. At the Alfred Mann Foundation, she led the team to evaluate, prioritize and monetize research projects. These plans translated to two projects that were spun out into two companies, Axonics Modulation and Medallion Therapeutics. She has led strategy facilitation sessions including scenario planning for commercial, payor and competition strategies. Axonics Modulation is now publicly traded. Focus is on small to mid size companies developing and understanding what it takes to develop a Go-to-Market Strategy and enabling market access for your products. |
Images: All images purchased from 123rf.com